Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Anti-CD20 mAbs were originally created to treat B cell proliferative diseases such as non-Hodgkin's lymphoma and chronic ...

Joint injury induces rapid and sustained diversification of resident and infiltrating synovial macrophage phenotypes, underpinning osteoarthritis-associated synovitis.

Inhibition of nonsense-mediated decay turns immunologically cold tumors hot by increasing the amount of mutant RNA leading to an increase in T-cell-targetable neoantigens on the cell surface.

SignalChem Biotech, part of Sino Biological, offers one of the largest active enzyme collections in the world and specializes ...

Risk factors for secondary skin cancer after blood or marrow transplant include those who had treatment with a monoclonal ...

Wide areas of the pharmaceutical industry are ripe for enhancement, as examples from the industry’s top innovators reflect.

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its ...

The growth of the cell culture media market is driven by rising demand for biopharmaceuticals, vaccines, and cell-based therapies, fueled by advancem ...

Cell line development plays a pivotal role in the manufacturing of therapeutic proteins, vaccines and other biologics.